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5ABSTRACT
Title of the study-
“ A case control study of Lipoprotein a levels in patients with atherosclerotic 
peripheral arterial occlusive disease”
DEPARTMENT Vascular Surgery, CMC- Vellore
NAME OF THE CANDIDATE                      Rajesh Joseph Selvakumar
DEGREE AND SUBJECT                              MS (General Surgery)
NAME OF GUIDE                            Dr. Sunil Agarwal
OBJECTIVE:
To determine the proportion of patients with atherosclerotic peripheral arterial occlusive 
disease (PAOD) who have elevated Lipoprotein (a) [Lp (a)] levels.
METHODS: 
This was a prospective, non-randomized, case-control study conducted among patients who 
presented with symptomatic atherosclerotic peripheral arterial occlusive disease. Informed 
consent was taken for the cases and controls and the patients were subjected to a fasting 
blood sample of serum Lipoprotein a which was analysed in the Biochemistry laboratory. 
RESULTS: 
Elevated Lp (a) levels were found in 89.1% of the cases as opposed to 54.5% of the control 
population with an odds ratio of 6.8 with a p value of <0.001(95% CI 2.5-18.5). The type of 
presentation did not correlate with elevated Lp (a) levels. Other atherosclerotic risk factors 
did not have a statistically significant effect on Lp (a) levels suggesting that Lp (a) was an 
independent risk factor leading to the development of PAOD. 
6INTRODUCTION:
Peripheral arterial occlusive disease (PAOD) is a major contributor to hospitalisations to any 
Vascular Surgery Unit, worldwide. The prevalence of PAOD is on the rise around the world; 
more alarmingly among developing nations like ours.  The majority of hospitalisations (both 
diagnostic and therapeutic) for lower limb arterial insufficiency worldwide are linked to 
PAOD. Since the current standard of care for atherosclerotic PAOD involves a multi-
modality approach of risk factor reduction by life style modification, medications and 
interventions which include surgical and endovascular repairs, the financial burden of this 
disease is immense.
The risk factor profile for atherosclerotic PAOD encompasses the traditional risk factors 
associated with cardiac atherosclerotic vascular disease, which include age, smoking, 
dyslipidemia, diabetes mellitus and hypertension. Studies have demonstrated an association 
with elevated Lp (a) and cardiac atherosclerosis.  Lp (a) accelerates atherosclerosis at various 
levels; starting from increased endocytosis of VLDL by macrophages in the arterial wall, to 
inhibiting clot lysis.  Recent data from studies done in an Indian population corroborates the 
above; demonstrating a correlation between elevated Lp (a) levels and CAD.
Based on this information, therapeutic measures to lower Lp (a) levels have been 
demonstrated to improve outcomes in coronary artery disease. Since atherosclerotic PAOD 
shares the same risk factor profile as CAD, it is hypothesized that Lp(a) levels may be 
elevated in atherosclerotic PAOD patients. 
Our study aims to determine whether there is a correlation between elevated Lp (a) levels and 
atherosclerotic PAOD. If so, further studies need to be undertaken to demonstrate whether 
lowering of Lp (a) in these patients contributes to improving patient outcomes. 
7Despite being included under the broad category of developing nations, the majority of 
India’s population lives in rural and semi urban settings; where access to a tertiary care centre 
equipped to perform interventions, are limited. Thus, interventions to lower Lp(a) levels 
might have tremendous implications in the treatment of atherosclerotic PAOD in resource 
limited settings like ours.
8RELEVANCE OF THE STUDY
The role of Lp(a) in coronary artery disease has been extensively studied and its role in 
atherosclerosis and thrombogenesis has been proved. The role of reducing Lp(a) levels in this 
subgroup of patients and the benefits achieved after lowering Lp(a) levels still remain 
controversial. The indications for lowering Lp(a) level also is still debated. However the role of 
Lp(a) in PAOD has not been studied in detail and there is still clear lack of evidence showing 
elevated levels of Lp(a) in patients with PAOD. No studies have been done to look at Lp(a) 
levels in an Indian population with atherosclerotic risk factors with PAOD.
9AIMS AND OBJECTIVES
AIM:
To determine the proportion of patients with atherosclerotic peripheral arterial occlusive 
disease (PAOD) who have elevated Lp(a) levels.
OBJECTIVES:
1. To determine whether Lp(a) levels are elevated in patients with atherosclerotic PAOD.
2. To determine whether Lp(a) levels can be used as an independent predictor of 
atherosclerotic PAOD  in symptomatic patients.
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REVIEW OF LITERATURE:
EPIDEMIOLOGY OF PAOD:
Though classically described as a disease of developed nations, the prevalence of PAOD is
on the rise worldwide. The prevalence of PAOD increases gradually with age, commencing 
after age 40(1-3).  The 1999 to 2000 National Health and Nutrition Examination Survey 
(NHANES) was then first to quantitatively describe the relationship between increasing age 
and the prevalence of PAOD(3).  According to this survey, the prevalence of PAOD, which 
was described as an ankle-brachial index (ABI) <0.90 in either leg, was 0.9 percent in the 
age group between 40 and 49, 2.5 percent in the age group of 50 and 59, 4.7 percent in the 
age group between 60 and 69, and 14.5 percent age 70 and older(3). However, the 
PARTNERS program, a study conducted among primary care practices in the United States, 
showed an overall higher prevalence of PAOD(4). PAOD was present in 29 percent overall: 
13 percent had PAD alone (55 percent newly diagnosed) and 16 percent had PAOD and 
cardiovascular disease (35 percent newly diagnosed) (4). Interestingly, only 11 percent of 
patients with PAOD presented with a classic history of claudication, as described below (4). 
Thus PAOD contributed greatly to the number of hospitalisations involving diagnostic and 
therapeutic measures for lower limb arterial insufficiency (5).
RISK FACTORS FOR PAOD:
The risk factor profile for patients with PAOD resembles that of patients with cardiac 
atherosclerotic disease. Based, in part, upon the observations of the Framingham Heart Study
(6) the 2005 American College of Cardiology/American Heart Association (ACC/AHA) 
guidelines on PAOD, which were produced in collaboration with major vascular medicine, 
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vascular surgery, and interventional radiology societies, identified the following groups at 
risk for lower extremity PAOD:
ß Age ≥70 years.
ß Age 50 to 69 years with a history of smoking or diabetes.
ß Age 40 to 49 with diabetes and at least one other risk factor for atherosclerosis.
ß Leg symptoms suggestive of claudication with exertion or ischemic pain at rest.
ß Abnormal lower extremity pulse examination.
ß Known atherosclerosis at other sites (eg, coronary, carotid, or renal artery disease).
The Framingham Heart study demonstrated the following results. There was an odds ratio of 
1.2 for developing intermittent claudication with each 40 mg/dL (1 mmol/L) elevation in the 
serum cholesterol concentration, 1.4 for each 10 cigarettes smoked per day, 1.5 for mild and 
2.2 for moderate hypertension, and 2.6 for diabetes mellitus [6]. Also, as per this study, 
diabetics have more advanced arterial disease and poorer outcomes than nondiabetic patients
(6).
Further studies detailing the lipid profile and the lipid metabolism in patients with PAOD (7) 
demonstrated that patients with PAOD are more likely to have abnormalities in other aspects 
of the lipid profile such as triglycerides, cholesterol, apolipoprotein B, and very low density 
lipoprotein (7). Also, risk of intermittent claudication may also be increased in patients with 
elevated plasma Lp(a) and fibrinogen levels (7).
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CLINICAL FEATURES:
A majority of patients with PAOD do not exhibit any symptoms and are incidentally detected 
while ABPI screening. Also, classical claudication is seen among 10 to 35% of symptomatic 
patients. As per the 2005 ACC/AHA guidelines on PAOD, the distribution of clinical 
presentation of PAOD in patients ≥50 years of age is as follows:
ß No symptoms – 20 to 50%
ß Atypical pain in the legs – 40 to 50%
ß Claudication – 10 to 35%
ß Critical limb ischemia – 1 to 2%
Classification —
The classification systems commonly used worldwide for chronic lower extremity PAOD 
are: the Fontaine system and the Rutherford system. 
Both are based upon the symptomatology and the presence of clinical markers for severe 
chronic occlusive disease, such as ulceration and gangrene (5).
Fontaine staging of PAOD:
Stage Clinical
I Asymptomatic
IIa Mild claudication
IIb Moderate to severe claudication
III Ischemic rest pain
IV Ulceration or gangrene
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Rutherford categories of PAOD:
Grade Category Clinical
0 0 Asymptomatic
I 1 Mild claudication
I 2 Moderate claudication
I 3 Severe claudication
II 4 Ischemic rest pain
III 5 Minor tissue loss
III 6 Major tissue loss
Symptomatic disease:
Claudication pain might vary from mild with no effect on activities of daily living to severe 
and disabling rest pain. The severity of pain is determined by the degree of occlusion to the 
vessel, amount of collateral vessel formation, and the intensity of exercise. Based on the 
anatomic site of arterial occlusive disease, the location of the pain varies as follows:
ß Buttock and hip – aorto-iliac disease
ß Thigh – aorto-iliac or common femoral artery
ß Upper two-thirds of the calf – superficial femoral artery
ß Lower one-third of the calf – popliteal artery
ß Foot claudication – tibial or peroneal artery
Physical examination in the patient with claudication may reveal no abnormality, but usually
reveals decreased or absent pulses distal to the level of the stenotic lesion. Other signs such 
as bruits over stenotic lesions and delayed healing of wounds over the area of distribution of 
the vessel. The affected extremity may be cool and clammy, with prolongation of venous 
filling. Skin over the limb may be shiny and atrophied and there may be nail changes. The 
absence of hair is not a clinical predictor of the presence of PAOD.
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Physical signs can also help determine the extent and distribution of vascular disease. These 
include an abnormal femoral pulse, lower extremity bruits, and the Buerger test (foot pallor 
with elevation of the leg and, in the dependent position, a dusky red flush spreading 
proximally from the toes).
Buttock and hip claudication: When the level of occlusion is at the aorto-iliac segment 
patients complain of pain at the buttock or the hip. In some instances claudication at the thigh 
may also be seen. Erectile dysfunction may be seen in patients with bilateral aorto- iliac 
disease. Leriche syndrome is the triad of claudication, absent or diminished femoral pulses 
and erectile dysfunction.
Thigh claudication: Pain in the thighs and calf is seen in patients with lesions at the level of 
the common femoral artery. When the lesion is at the level of the superficial femoral artery or 
distal to this segment patients may have normal groin pulses.
Calf claudication: Calf claudication is the commonest presenting symptom. It is defined as 
pain that increases in intensity as the patient continues to walk and subsides with 
discontinuation of the activity. Claudication pain involving the upper half indicates 
superficial femoral artery lesions and claudication pain involving the lower half indicates 
popliteal lesions.
Foot claudication — Atherosclerotic lesions of the tibial and peroneal vessels prsents as foot 
claudication. However, this symptom is more commonly associated with thromboangiitis-
obliterans (TAO).
Ischemic rest pain — A severe lowering of the baseline limb perfusion produces ischemic 
rest pain. This is classically described as pain which is worse at night and is relieved by 
keeping the foot in a dependant position or by walking. This is due to increase on perfusion 
due to the effect of gravity.
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DIAGNOSIS:
The diagnosis of PAOD is made based on a thorough history and detailed physical 
examination. The role of non-invasive vascular studies is only as an adjunct to confirm a 
clinical diagnosis. Non-invasive investigations used in the evaluation of the patient include: 
calculation of pressure index values (eg, ankle-brachial index, wrist-brachial index), exercise 
testing, segmental volume plethysmography, transcutaneous oxygen measurements and 
photo-plethysmography.
Ultrasound based imaging is the commonest method of vascular imaging. This provides 
various modes (eg, B-mode, duplex), which are crucial in acquiring specific information 
pertinent to the vascular disorder. With the arrival of more advanced technology, such as 
computed tomography (CT) and magnetic resonance (MR) imaging, more accurate and 
detailed evaluation of the vascular anatomy is possible. Thus, CT angiogram is the gold 
standard of evaluation; especially prior to any intervention; surgical or radiological.
Ankle-brachial index- This is the simplest and cheapest method of confirming arterial 
insufficiency (9). This involves comparison of the resting systolic blood pressure at the ankle 
with the systolic brachial pressure. The ratio of the two pressures is defined as the ankle-
brachial index. 
The patient rests for 15 to 30 minutes prior to measuring the ankle pressure. A blood pressure 
cuff is placed just above the ankle. While either the dorsalis pedis or posterior tibial artery 
signal is continuously monitored with a continuous wave Doppler, the cuff is insufflated to a 
pressure above which the audible Doppler signal disappears. The pressure is then slowly 
released until the pedal signal returns and this systolic pressure is recorded.  The 
measurement is repeated in the same manner for the other pedal vessel in the ipsilateral 
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extremity and then repeated for the contralateral lower extremity. The systolic brachial artery 
pressure is measured bilaterally in a similar fashion with the blood pressure cuff placed 
around the upper arm and using the continuous wave Doppler. The ABI for each lower 
extremity is calculated by dividing the higher ankle pressure (dorsalis pedis or posterior tibial 
artery) in each lower extremity by the higher of the two brachial artery systolic pressures.
The disadvantage of using continuous wave Doppler is a lack of sensitivity at extremely low 
pressures where it may be difficult to distinguish arterial from venous flow (10).
The ABI roughly correlates with clinical indicators of lower extremity function such as 
walking distance, speed of walking, balance, and overall physical activity. Further evaluation 
is dependent upon the ABI value-
∑ ABI ≥0.9 to 1.3- normal. A Normal ABI generally excludes arterial disease, however 
mild disease and certain arterial entrapment syndromes produce false results and 
warrant exercise testing (11). 
∑ ABI >1.3 suggests calcified vessels and suggests the need for other vascular studies, 
such as pulse volume recordings, measurement of the toe pressures and toe-brachial 
index, or arterial duplex studies.
∑ ABI ≤0.9 is diagnostic of arterial occlusive disease in patients with symptoms of 
claudication or other signs of ischemia. It has 95 percent sensitivity (and 100 percent 
specificity) for detecting occlusive lesions which are already established on an 
angiogram which demonstrate ≥50 percent stenosis in one or more major vessels
(12).
∑ ABI of 0.4 to 0.9 suggests a degree of arterial obstruction often associated with 
claudication.
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∑ An ABI below 0.4 represents multilevel disease (any combination of iliac, femoral or 
tibial vessel disease) and may be associated with non-healing ulcerations, ischemic 
rest pain or pedal gangrene.
A low ABI is an indicator of higher risk for more ominous comorbidities such as
coronary heart disease, cerebrovascular accidents, progressive renal insufficiency, and is 
also associated with an increase in all-cause mortality (13). 
In patient with advanced disease, high ABI values are associated with calcification of the 
vessels which may not compress normally. This results in falsely elevated pressure 
measurements. Therefore in the appropriate clinical setting, an ABI of more than 1.3 is 
suspicious for calcification of vessels (14).
Wrist-brachial index— The wrist-brachial index (WBI) is used to identify the level and 
extent of upper extremity arterial occlusive disease. 
Toe-brachial index- Is more reliable in patients with diabetes since the small vessels of 
the toes are spared from calcification. The great toe is usually used but in case of 
amputation the second or other toes can be used to measure the TBI. A photo-electrode is 
placed on the end of the toe to obtain a photoplethysmographic (PPG) arterial waveform 
using infrared light.
Transcutaneous oxygen measurement- (TcPO2) helps assimilate supplemental 
information with respect to local tissue perfusion. Also, this modality aids in assessment 
and monitoring of the healing potential of ischemic ulcers or amputation sites. Platinum 
oxygen electrodes are placed on the chest wall and lower limbs. Two values may be used: 
the absolute value of TcPO2 or the ratio between the chest and foot values. The normal 
TcPO2 level at the foot is 60 mmHg and the normal TcPO2 chest/foot ratio is 0.9(15). 
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However, local edema, variations in cutaneous temperature, highly emotional states (
leading to peripheral sympathetic vasoconstriction), inflammation, and use of 
pharmacologic agents limit the precision of the test.
Imaging modalities
Ultrasound- Ultrasonography is used to evaluate the location and extent of vascular 
disease, arterial hemodynamics, and lesion morphology (16). The B-mode (brightness 
mode) and Doppler mode used together, each providing specific information has become 
a mainstay in vascular imaging. 
B-mode provides a grey scale image useful for evaluating anatomic detail and the 
Doppler detects   flow of blood across the vessels. Combining the two modes Duplex 
ultrasound has gained a prominent role in the noninvasive assessment of the peripheral 
vasculature. It overcomes the need for intra-arterial contrast and provides precise 
anatomic localization and accurate grading of lesion severity (17). 
Depending on the site of the vessel to be studied probes with varying frequencies have 
been used. Assessment of the aorto-iliac segment and the renal vessels could be obscured 
due to gas in the bowel and due to the depth of these vessels and thus low frequency 
probes are used. 
Contrast arteriography- Digital subtraction angiography remains the best modality for 
vascular imaging and can also be used in the setting of acute limb ischemia. Limitations 
include: radiation exposure and complications of arterial access. Owing to these 
limitations, other non-invasive methods like CT angiography and MR angiography are 
preferred.
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The multi-detector computed tomography (MDCT) helps rapidly acquire high resolution, 
contrast-enhanced arterial images (18). The MDCT although inexpensive involves 
radiation exposure and injection of contrast material. The sensitivity and specificity for 
detecting a stenosis of ≥50 percent with MDCT and DSA were 95 and 96 percent, 
respectively.
Magnetic resonance angiography (MRA), using gadolinium contrast has shown to be a 
time-efficient and cost effective (cheaper than DSA) modality in the evaluation of PAOD. 
However, the tendency of gadolinium for inducing nephrogenic systemic fibrosis (NSF) 
in patients with renal insufficiency, limits its clinical use. 
TREATMENT:
After confirming the diagnosis of PAOD, the management of PAOD involves a combined 
approach incorporating the following measures: 
- Risk factor modification of hypertension, diabetes, obesity and hyperlipidemia
- Lifestyle modification including smoking cessation
- Pharmacotherapy 
- Exercise to increase walking tolerance
- Interventional therapy (eg, balloon angioplasty, stenting, atherectomy, 
endarterectomy, and surgical bypass).
-
1. RISK FACTOR MODIFICATION:
PAOD shares common risk factors with atherosclerotic disease elsewhere in the body; 
including coronary and carotid atherosclerotic disease. In fact according to the third 
20
report of the National Cholesterol Education Program (NCEP) Expert Panel on 
detection, evaluation, and treatment of high blood cholesterol in adults (Adult 
Treatment Panel [ATP] III), PAOD is described as a coronary heart disease risk 
equivalent(19).
Diabetes Mellitus: Though aggressive control of blood sugar in both type 1 and type 
2 diabetes reduces the risk of micro-vascular complications (eg, nephropathy, 
retinopathy, and neuropathy), there is no evidence to suggest that aggressive 
glycaemic control reducing the risk and progression of macro-vascular complications; 
including PAOD(20,21).
Hypertension: Currently there is no data evaluating whether antihypertensive 
therapy alters the progression of claudication. However, aggressive optimisation of 
blood pressure in these patients helps reduce morbidity from cardiovascular and 
cerebrovascular disease (5).
Hyperlipidemia: Studies performed even prior to the introduction of statin therapy 
for dyslipidemia, showed regression or less progression of femoral atherosclerosis 
with lipid-lowering therapy (22,23), and a decrease in the incidence of claudication
pain and limb-threatening ischemia in patients with hyperlipidemia who were treated 
with surgery (24).
The following benefits have been noted with statin therapy for PAOD:
- Regression of femoral atherosclerosis (25), 
- a lower rate of new or worsening claudication (26),
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- improvements in walking distance and pain-free walking time (27,28)
- lowers the incidence of cardiovascular events in patients with PAOD (29)
Recommendations regarding lipid control made in the 2007 TASC II consensus document 
on the management of PAOD (5):
ß Target LDL-cholesterol for patients with PAOD is <100 mg/dL (2.6 mmol/L).
ß Target LDL-cholesterol to <70 mg/dL (1.8 mmol/L) is preferred in patients with 
PAOD and cerebrovascular or cardiac atherosclerosis.
2. LIFESTYLE MODIFICATION:
The progression of PAOD can be stopped with smoking cessation (30,31). There is no 
consensus whether cessation of tobacco use reduces the severity of claudication 
symptoms. In a meta-analysis (32) that looked at pain-free and total walking distance 
outcomes, smoking cessation was found useful, but only in nonrandomized trials.
The following recommendations regarding smoking cessation were made in the 2011 
update to the ACC/AHA guidelines (33) for the management of patients with PAOD, 
and the 2007 TASC II consensus document(5) on the management of PAOD:
ß All patients who have a history of smoking (i.e) are smokers or former smokers 
should be questioned about the status of tobacco use at every hospital visit
ß All patients should be strongly counselled to stop smoking by their physicians
ß All patients should be given pharmacotherapy, behavior modification, referral to a 
smoking cessation program, and counselling.
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3. PHARMACOTHERAPY:
Pharmacological therapy is aimed at reduction of symptoms of claudication and 
slowing the course of natural disease. Many agents have been evaluated, however 
evidence for use has been convincing only for Cilostozol and antiplatelet agents ( 
33,34). 
1. Cilostozol- This drug is a phosphodiesterase inhibitor. Due to this action it 
acts directly on the arteries; leading to arterial vasodilation. It supresses 
platelet aggregation (35). Benefits of therapy are seen as early as within 4 
weeks of initiation of treatment. Cilostazol is indicated for increasing walking 
distance among those patients with PAOD, in whom antiplatelet agents and 
exercise rehabilitation have failed and revascularisation is not possible (5,34). 
Cilostazol is well tolerated; even with antiplatelet medications like aspirin 
and/or Clopidogrel.
2. Antiplatelet agents- The currently available data suggests that there is no 
improvement or only a modest improvement of claudication with antiplatelet 
agents alone. Therefore, the indication for use is for secondary prevention of 
coronary disease and stroke. 
Of the available antiplatelet agents- Asprin, Ticlopidine, Dipyridamole and 
Clopdiogrel, Asprin remains the drug of choice as it is cost effective and 
reduces coronary disease and stroke. 
Ticlopidine was found to have best efficacy in terms of increase in walking 
distance (37) but side effects such as leukopenia and thrombocytopenia, 
requiring close hematologic monitoring for at least three months were seen. 
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Other unwanted effects include bleeding diathesis, dyspepsia, loose stools, 
nausea, anorexia, and giddiness. 
Clopidogrel is similar to ticlopidine but considered a safer drug in terms of 
side effects. The CAPRIE trial demonstrated that clopidogrel (75 mg/day) had 
a minimal, although significant benefit over aspirin (325 mg/day) for the 
prevention of stroke, myocardial infarction (MI), and PAOD (38). 
Antiplatelet summary (33,5)
The role of antiplatelet therapy is to reduce the risk of consequences of other 
atherosclerotic vascular disease like MI, stroke, and vascular death in 
individuals with symptomatic atherosclerotic lower extremity PAOD, 
including those with claudication.
Aspirin is preferred and clopidogrel is indicated in settings which preclude the 
use of Aspirin.
3. Pentoxifylline- is a rheologic modifier which acts by increasing deformability 
of red cells and blood viscosity, decreases in fibrinogen concentration, and 
reduced platelet adhesiveness. Data suggests that Pentoxifylline is of 
questionable benefit and that its results can be matched with walking regimens 
alone (39). 
Other rheologic modifiers- Hydroxy-ethyl starch (HES) or a low-molecular-
weight dextran (LMWD) one to two times weekly for several weeks have been 
used for decreasing the blood viscosity and hemodilution. There is very 
minimal benefit and thus this therapy is not recommended(40,41).
4. Naftidrofuryl- a 5-hydroxytryptamine-2-receptor antagonist whose 
mechanism of action of action is unclear but it is hypothezised to increase the 
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peripheral uptake of glucose; thereby leading to an increase in ATP levels 
(42). 
5. Ginkgo biloba- Though this was presumed to have antioxidant effect, and 
antithrombotic effects, ACC/AHA guidelines concluded that there was no 
benefit from this therapy (8,33). 
Investigational agents- The following agents have been proposed but these are 
not recommended yet-
∑ Angiotensin inhibition- Ramipril might provide symptomatic benefit in 
patients with claudication (43). Further studies are required before the use 
of ACE inhibitors for claudication can be recommended.
∑ Antichlamydophila therapy- It has been proposed that Chlamydophila 
(formerly Chlamydia) pneumoniae infection may promote the 
development of atherosclerosis and treatment with Roxithromycin 
prevents progression of disease (44). These observations need to be 
confirmed on a larger basis. 
∑ Propionyl-L-carnitine- This is hypothezised to act by increasing energy 
metabolism in ischemic muscle (45,46). A double-blind placebo-controlled 
study reported improvement in quality of life, emotional status, and 
physical function among a subset of patient with more severe limitation of 
their walking capacity (<250 meters) at baseline (47). But, ACC/AHA 
guidelines concluded that benefit from this therapy is questionable (8,33). 
∑ Defibrotide- is an agent that is hypothesised to stimulate fibrinolysis by
increasing the release of tissue plasminogen activator and prostacyclin and 
reducing the release of plasminogen activator inhibitor from endothelial 
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cells. A placebo-controlled study evaluating its effects reported an 
increased maximal treadmill walking distance over a six-month period
(48).
∑ Prostaglandins- PGE1 is a vasodilator and causes inhibition of  
aggregation of  platelets. It is metabolised rapidly in the lungs and thus 
needs to be administered at high doses. Studies showed an increase in 
walking distance and improvement in quality of life when it was 
administered in its prodrug form (49). A Cochrane review of five studies 
comparing PGE1 (alprostadil) with placebo found that significant 
increases in walking distances were attained with PGE1, which persisted 
even after termination of treatment (50). 
4. SUPERVISED EXERCISE THERAPY:
Both hospital and community based exercise programs have been useful in reducing 
the claudication pain in patients with PAOD (51-56). Although community based 
programs are associated with higher dropout rates, they still provide psychological 
support which is essential in any successful exercise program. 
Mechanisms by which exercise training may improve claudication-
∑ Improved endothelial function increases endothelial-dependent dilation (57). 
∑ Reduced local inflammation (induced by muscle ischemia) by decreasing free 
radicals (58).
∑ Increased exercise pain tolerance (59).
∑ Induction of vascular angiogenesis (60).
∑ Improved muscle metabolism by favourable effects on 
muscle carnitine metabolism and other pathways (61).
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∑ Reduced red cell aggregation and in blood viscosity (62).
5. INTERVENTIONAL THERAPY:
TASC classification- Lesions have been classified as follows:
A) AORTO-ILIAC LESIONS
TASC classification of aorto-iliac lesions
Type A lesions Unilateral or bilateral stenoses of CIA  
Unilateral or bilateral single short (≤3 cm) 
stenosis of EIA
Type B lesions Short (≤ 3cm) stenosis of infrarenal aorta 
Unilateral CIA occlusion 
Single or multiple stenosis totaling 3–10 cm 
involving the EIA not extending into the CFA 
Unilateral EIA occlusion not involving the 
origins of internal iliac or CFA
Type C lesions Bilateral CIA occlusions 
Bilateral EIA stenoses 3–10 cm long not 
extending into the CFA 
Unilateral EIA stenosis extending into the CFA 
Unilateral EIA occlusion that involves the 
origins of internal iliac and/or CFA 
Heavily calcified unilateral EIA occlusion with 
or without involvement of origins of internal 
iliac and/or CFA
Type D lesions Infra-renal aortoiliac occlusion 
Diffuse disease involving the aorta and both 
iliac arteries requiring treatment 
Diffuse multiple stenoses involving the
unilateral CIA, EIA and CFA 
Unilateral occlusions of both CIA and EIA 
Bilateral occlusions of EIA 
Iliac stenoses in patients with AAA requiring 
treatment and not amenable to endograft 
placement or other lesions requiring open 
aortic or iliac surgery
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Treatment of aortoiliac lesions: 
• TASC A and D lesions: The treatment of choice for type A lesions is endovascular therapy 
and for type D lesions is surgery. 
• TASC B and C lesions: The preferred treatment for type B lesions is endovascular therapy 
and for patients with type C lesions who do not have other co-morbid illnesses or those in 
whom the co-morbid illnesses are under control surgery is the preferred modality. 
The patient is informed about the operators expertise and the risk factors associated with the 
various co-morbid illnesses before making treatment recommendations for both type B and C 
lesions. 
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B) FEMORAL POPLITEAL DISEASE
TASC classification of femoral popliteal lesions:
Type A lesions Single stenosis ≤10 cm in length 
Single occlusion ≤5 cm in length
Type B lesions Multiple lesions (stenoses or occlusions), each ≤5 cm 
Single stenosis or occlusion ≤15 cm not involving the 
infra geniculate popliteal artery 
Single or multiple lesions in the absence of continuous 
tibial vessels to improve inflow for a  distal bypass 
Heavily calcified occlusion ≤5 cm in length 
Single popliteal stenosis
Type C lesions Multiple stenoses or occlusions totaling >15 cm with 
or without heavy calcification 
Recurrent stenoses or occlusions that need treatment 
after two endovascular interventions
Type D lesions Chronic total occlusions of CFA or SFA (>20 cm, 
involving the popliteal artery) 
Chronic total occlusion of popliteal artery and 
proximal trifurcation vessels
Treatment of femoral popliteal lesions:
As in aorto-iliac disease the treatment for type A lesions is endovascular repair and for type D 
lesions is surgery. Type B and C lesions can be treated either by endovascular repair or 
surgery depending on the comorbid illnesses of the patient and the expertise of the operator. 
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INDICATIONS FOR REVASCULARIZATION — The ACC/AHA and other guidelines 
suggest that the following issues need to be addressed when considering either percutaneous 
or surgical revascularization in patients with intermittent claudication (5,8):
ß Lack of adequate response or failure of exercise rehabilitation and pharmacologic 
therapy.
ß Significant disability due to claudication; as indicated by an inability to perform 
normal work or activities of daily living. This criterion indicates the symptom 
variability among patients with claudication and of the impact of these symptoms on 
the quality-of-life. 
ß The patient is able to benefit from an improvement in claudication (ie, exercise is not 
limited by another cause, such as angina, heart failure, chronic obstructive pulmonary 
disease, or orthopedic problems).
ß Based on the evolution of the disease as seen in the natural history and prognosis of 
the patient.
ß The characteristics of the disease permit appropriate intervention at low risk to the 
patient with a high chance of immediate and long-term success. 
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ROLE OF LIPOPROTEIN A :
Prior studies which evaluated the role of pharmacological management of dyslipidemia for 
the prevention of cardiovascular disease (CVD) focused on patients with elevated LDL-
cholesterol levels. Despite evidence that other dyslipidaemias, like an elevated level of Lp 
(a), have also been shown to accelerate atherosclerosis, there is a dismal lack of clinical trial 
evaluating interventions directed toward lowering Lp (a) levels (63). Elevated serum Lp (a), 
is  currently included as an independent risk factor for CVD. Also, there is direct correlation 
between high Lp (a) levels and patients presenting with an acute myocardial infarction.
STRUCTURE AND FUNCTION:
Lp (a) is a modified form of low density lipoprotein (LDL) in which a large glycoprotein, 
apolipoprotein (a) [apo(a)] is covalently bound to apolipoprotein B by a disulfide bridge (64). 
The apo (a) chain contains five cysteine rich domains known as "kringles"(65). The fourth 
kringle is similar in structure with the fibrin-binding domain of plasminogen, which is a 
plasma protein that dissolves blood clots when activated. Because of this structural similarity 
to plasminogen, Lp (a) interferes with fibrinolysis by competing with plasminogen binding to 
molecules and cells. This impairs plasminogen activation, plasmin generation, and 
fibrinolysis (66,67). Lp (a) also binds to macrophages via a high-affinity receptor that 
promotes foam cell formation and the deposition of cholesterol in atherosclerotic plaques.
GENETICS :
Lp(a) is an important molecule because its levels are mainly genetically determined and are 
not influenced by environmental factors , including the classical vascular risk factors.  In 
families without familial hypercholesterolemia, greater than 90 percent of the variability in 
Lp(a) levels can be explained by polymorphisms at the apo(a) gene locus (isoforms), also 
referred to as the LPA gene (Online Mendelian Inheritance in Man [MIM] 152200) (68). One 
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important LPA polymorphism is the kringle IV type 2 size polymorphism, which results in a 
large number of differently sized isoforms of apolipoprotein (a) (70). There is a strong 
inverse relationship between the size of the apo (a) isoforms and the Lp (a) concentrations 
(68). A significant proportion (30 to 60 percent) of the population variation in Lp (a) levels is 
determined by this polymorphism (69).
EPIDEMIOLOGY:
The distribution of Lp (a) varies with race and ethnicity. Lp (a) levels are normally 
distributed in African-American populations. However, Caucasians, Eastern Asian, and Asian 
Indian populations have Lp(a) distributions where the baseline levels are lower than those of 
their African-American counterparts (70). According to the Framingham Heart Study, the 
90th percentile of Lp (a) levels is 39 mg/dL (1.39 µmo/L) in men and 39.5 mg/dL (1.41 
µmo/L) in women (units of mass) (71,72). 
Among Indians, a study based among healthy Indians in Mumbai provided the reference 
intervals for all apolipoproteins, in both sexes from a general population (73). Also, among 
subjects of South Indian origin, Delhi and Chennai based case control studies of Lp (a) levels 
among diabetics with CAD, showed a correlation between elevated Lp (a) levels and CAD 
(74,75). However, conflicting evidence was published by a Bangalore based study; which 
stated that there was no correlation with elevated Lp (a) levels and coronary artery disease 
(76).
In PAOD, the role of Lp (a) in the pathogenesis of PAOD is unclear. Also there is limited 
evidence which supports the above hypothesis (77). There is thus a clear lack of adequate 
data to determine the role of Lp(a) in PAOD. 
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Measurement of serum Lp (a) concentration-
Lp (a) was previously analysed using gel electrophoresis method; where it was seen as a 
heavy band occurring prior to the beta globulin (78). Density gradient ultracentrifugation 
used to be the standard method by which Lp (a) was measured. ELISA tests were then made 
available for measurement. But these methods were flawed as they were unable to distinguish 
between apo(a) isoforms, and had cross-reactivity with plasminogen, which lead to erroneous
estimation of Lp(a) levels (79,80). 
Currently there is a commercially available assay which uses a latex-enhanced 
immunoturbidimetric method that measures Lp (a) independently of the apolipoprotein(a) 
size and number of kringle-IV repeats (81,82). 
CARDIOVASCULAR DISEASE RISK:
Many small retrospective trials done in the early 1990s, demonstrated an association between 
elevated Lp (a) and cardiovascular disease (83-87). 
Coronary artery disease- A meta-analysis of 24 cohort studies confirmed the continuous 
association between Lp (a) and coronary artery disease (88). Another study among patients 
who suffered an acute myocardial infarct, elevated Lp (a) levels (>30mg/dl) was associated 
with a 62 percent increase in cardiac death in a three year follow up (89). 
Cerebrovascular disease- Elevated Lp (a) levels were found to be associated with an 
increased risk of cerebrovascular disease which was found to be stronger in men than in 
women (90, 91).
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Patients with hypertension- Elevated Lp (a) levels accelerates target organ damage in 
hypertensive patients. Lp (a) levels were found to be the best predictor of target-organ 
damage involving the kidney, heart, and arterial wall (92). 
MECHANISMS OF CVD RISK:
Atherothrombosis — A number of studies have been carried out to assess the role played by 
Lp (a) in atherothrombosis. Lp (a) excess is thought to promote atherosclerosis by the 
following mechanisms:
∑ The VLDL receptor found on the macrophages present in atherosclerotic lesions can 
bind to and mediate the catabolism of Lp (a) by endocytosis, leading to its 
degradation within lysosomes (93). This leads to accumulation of lipid within 
macrophages converting them into foam cells. 
∑ Binding to the endothelium and components of the extracellular matrix (94) and also 
endothelial dysfunction due to selective impairment of vasodilator capacity of the 
blood vessels (95). The importance of the latter effect is uncertain since Lp (a) may 
not impair nitric oxide-mediated vasodilation, in contrast to the demonstrated adverse 
effect of oxidized LDL (96). 
∑ Increased expression of intercellular adhesion molecule-1, which results in the 
recruitment of monocytes to the vessel wall and binding to macrophages (97). This 
promotes the formation of foam cells and the localization of Lp (a) in atherosclerotic 
plaques (98). 
∑ Interaction with the fibrinolytic and coagulation systems causing increased tissue-
factor mediated thrombosis and inhibition of clot lysis (99). 
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TREATMENT OF EXCESS LIPOPROTEIN A:
The indications for the treatment of Lp (a) have not been thoroughly investigated, although 
many clinicians are of the opinion that the primary goal of therapy is the reduce LDL 
cholesterol levels. 
LDL-C reduction — There are many clinicians who are more aggressive in LDL-C 
reduction in the presence of elevated Lp (a) levels. This is based on data which showed that 
there was a progression in coronary atherosclerosis and CHD events in the presence of 
elevated Lp (a) if the LDL-cholesterol levels were not lowered by more than 10 percent 
(100). 
Lp(a) reduction — When LDL-C levels cannot be optimally lowered, treatment for lowering 
Lp(a) is considered. 
∑ Nicotinic acid( Niacin) at a dose of 2 to 4gm/day is initiated for reduction of Lp (a)
(101). Niacin also reduces LDL-C and has beneficial effects on the lipid profile. Other 
salutary effects such as reduction of LDL-C, apo B-100, small LDL, and triglycerides 
and elevation of HDL-cholesterol levels have been shown. As much as 38 percent 
reduction of Lp (a) levels have been shown with treatment with Niacin (101). 
∑ Neomycin at a dose of 2 to 3gm/day also reduces Lp (a), but is not used due to its 
numerous side effects (102). It has been shown to reduce Lp (a) levels by nearly 24 
percent. 
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Lipid-lowering drugs — Other lipid lowering drugs have been shown to not have any effect 
on Lp (a). Statins and Fibrates used along with Niacin are beneficial in reducing the risk of 
coronary artery disease but do not have a direct effect on Lp (a) (103). 
NORMAL VALUE OF LIPOPROTEIN A:
Studies regarding the normal value of Lp (a) have shown that there is variation between 
various ethnic groups. Lp (a) levels were shown to be as high as three times more in certain 
African populations. The atherosclerosis risk in communities (ARIC) study found that there 
was a significant risk in stroke and cardiovascular disease in patients with Lp (a) levels more 
than 30mg/dl (104). 
Thus a Lp (a) level of below 30mg/dl was considered desirable to reduce the risk of stroke 
and cardiovascular disease (105).
The Lp(a) levels in the Indian population has not been studied in detail and there is a clear 
lack of knowledge if there is association with peripheral vascular disease. 
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MATERIALS AND METHODS
STUDY DESIGN
This is a case control study done among adult patients presenting with symptomatic 
atherosclerotic peripheral vascular disease, to the Department of Vascular surgery of 
Christian Medical College and Hospital, Vellore between August 2010 and December 2012.
Study setting:
Christian Medical College, Vellore is a 2200 bedded, tertiary care, multi-specialty teaching 
hospital in South India, which caters to the demands of patients not only from within 
Tamilnadu; but also to those from other states.
The Department of Vascular Surgery caters to patients with both arterial and venous diseases. 
The twice weekly Out Patient Clinic caters to approximately 120 patients with vascular 
disorders per day.  Approximately one fourth of these patients, present with arterial disorders.
A specialised Vascular Lab offers ABPI and Transcutaneous oxygen saturation (tcPO2) 
testing. About 12-15 operations are performed under the elective list and 2-5 emergency 
operations are performed on a weekly basis. Among these, 2-3 major arterial reconstructions 
are performed weekly.
APPROVAL:
This study was reviewed and cleared by the Institutional Review Board (IRB No: 7199) and 
the Ethics Committee of CMC Vellore.
Monetary funding of Rs.40,000 was provided by the Fluid Research Grant.
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INCLUSION CRITERIA:
SELCTION OF CASES:
1. All adult patients (>18years of age) with atherosclerotic risk factors (i.e.) smoking, 
dyslipidemia, hypertension and diabetes mellitus.
2. Symptomatic patients with ABPI <0.90 or with radiological evidence of peripheral 
arterial occlusive disease
SELECTION OF CONTROLS:
1. No symptoms, signs or radiological evidence of peripheral arterial disease
2. Controls will be matched for age and sex.
3. Controls will be chosen from patients attending the Vascular Surgery outpatient clinic 
and also from inpatients of Vascular Surgery Unit.
EXCLUSION CRITERIA: 
1. Patients with atherosclerotic PAOD on treatment with Niacin
2.   Thromboangitis oblietrans (TAO)
3. Vasculitis
4. Other non-atherosclerotic causes of PAOD
STUDY DURATION: 
1st August 2010 to 31st December 2012
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DATA COLLECTION:
Basic demographic data pertaining to the patient and details of risk factors at presentation, 
with clinical findings, ABPI or imaging findings, were noted on the data information sheets. 
A fasting sample for serum Lp (a) level estimation was drawn after obtaining informed 
consent from the patient.
SAMPLE SIZE CALCULATION:
Sample size was calculated based on the data available from a previous study conducted in 
2008 in Kuala Lumpur (77). 
Sample size:
Probability of exposure given disease absent 0.5
Anticipated odds ratio 3
Power (1- beta) % 0.75
Alpha error (%) 80
Error (%) 5
1 or 2 sided 2
Required sample size in each of the case &                              
control groups
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STUDY METHODOLOGY:
All symptomatic adult patients presenting with clinical or radiological evidence of PAOD to 
the Vascular Surgery Unit of Christian Medical College were screened and recruited for the 
study. Patients who were diagnosed to have TAO, vasculitis, or non-atherosclerotic causes of 
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PAOD or those who were already on treatment with Niacin for atherosclerotic PAOD, were 
excluded from the study.
Criteria for diagnosis of atherosclerotic PAOD:
Based on clinical examination, ABI and findings on imaging, patients were diagnosed to have 
PAOD on the following basis:
ß Leg symptoms suggestive of claudication with exertion or ischemic pain at rest.
ß Abnormal lower extremity pulse examination.
ß Abnormal ABPI
ß Radiological evidence of PAOD
Among those patients included in the study, basic epidemiological data including age, sex, 
disease location and risk factors was collected. 
Fasting serum samples were collected for estimation of lipoprotein (a) levels for all patients. 
All blood samples were collected in plain vacutainers, plasma separated and analysed by the 
Biochemistry laboratory. Lp (a) levels were analysed using immunoturbidometric assay . The 
assay was carried out in a Roche analyser, as per the manufacturer’s protocol.
STATISTICAL ANALYSIS:
The statistical method used to test association between categorical variables was the Chi 
square test of significance. Association between continuous variables was done using Pearson 
correlation coefficient. Microsoft Excel was used for data entry and SPSS Version 18 was 
used for statistical analysis. 
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RESULTS
The various parameters that were analysed through the course of this study were :
A. Baseline characteristics of the patients
∑ Age distribution
∑ Gender distribution
∑ Risk factor profile- diabetes, hypertension, dyslipidemia and tobacco use.
B. Symptoms at presentation.
C. Lp (a) levels of cases and controls 
D. Calculation of odds ratio
E. Logistic regression analysis
A. BASELINE CHARACTERISTICS: 
A total of 55 cases were selected and an equal number of controls were matched for age and 
sex. 
AGE: The age distribution of the patients was between 50 and 80 years. The mean age was 
60.32 (SD=8.32) years.
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Figure 1: Age distribution of patients with atherosclerotic PAOD N= 55: 
GENDER: A total of 46 male patients and 9 female patients were identified and equal 
number of controls were matched.
Figure 2: Gender distribution of patients with atherosclerotic PAOD N= 55:
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RISK FACTORS:
Of the identified patients 33(60%) cases and 37(67.37%) controls were diabetic, 26(47.27%) 
cases and 15(27.27%) controls were hypertensive, 16(29.09%) cases and 11(20%) controls 
were dyslipidemic and 45(81.81%) cases and 19(34.50%) controls used tobacco. 
DIABETES MELLITUS:
Figure 3: Prevalence of diabetes mellitus among cases and controls N= 110:
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HYPERTENSION:
Figure 4: Prevalence of hypertension among cases and controls N= 110:
DYSLIPIDEMIA:
Figure 5: Prevalence of dyslipidemia among cases and controls N= 110:
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TOBACCO USE:
Figure 6: Prevalence of tobacco use among cases and controls N= 110:
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The table mentioned below summarises the baseline characteristics of both patient 
populations (i.e) cases and controls.
Table 1- Shows the baseline characteristics of the cases and controls used in the study. 
Characteristic Cases
%(n)
Controls
%(n)
Total
%(N)
Gender
Male 83.36(46) 83.36(46) 83.36(92)
Age(years)
50-59
60-69
70-79
>=80
49.09(27)
34.54(15)
14.54(8)
0.01(1)
49.09(27)
34.54(15)
14.54(8)
0.01(1)
49.09(54)
34.54(30)
14.54(16)
0.01(2)
Diabetes 60.00(33) 67.20(37) 63.63(70)
Hypertension 47.27(26) 27.27(15) 37.27(41)
Dyslipidemia 29.09(16) 20.00(11) 24.54(27)
Tobacco use 81.81(45) 34.50(19) 58.18(64)
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B. SYMPTOMS AT PRESENTATION:
Among cases, the commonest presenting symptom was gangrene (34.54%). However, 
claudication(29.09%) and rest pain(27.27%) were seen in almost similar numbers.
Figure 7- Presenting symptoms among cases N=55: 
Table 2- Correlation between type of presentation and Lp(a) levels. 
Presentation Lp (a)< 30
%(n)
Lp (a) >= 30
%(n)
Acute limb ischemia 0%(0) 11%(5)
Gangrene 5.4%(3) 29.09%(16)
Rest pain 1.8%(1) 25.45%(14)
claudication 3.6%(2) 29.09%(14)
Total %(n) 10.9%(6) 89.09%(49)
Table 2 indicates that there was no association between the severity of presentation and 
elevated Lp(a) levels (p= 0.706)
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C. Lp (a) LEVELS AMONG CASES AND CONTROLS:
Lp (a) levels were elevated in a greater proportion of cases (89.1%) (i.e) patients with 
documented PAOD.  Among controls more than half (54.5%) of the patients also had 
elevated Lp (a).
Figure 8- Lipoprotein levels among cases and controls N=110: 
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Figure 9- Scatter diagram showing the distribution of Lp (a) levels among cases
The mean Lp (a) level among the cases was 103.23mg/dl with a standard deviation of 69.97.
Figure 10- Scatter diagram showing the distribution of Lp (a) levels among controls
The mean Lp (a) level among the controls was 44.58mg/dl with a standard deviation of 38.14.
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D. CALCULATION OF ODDS RATIO:
Odds ratio was calculated and a Chi-square test was performed to check the significance of 
elevated Lp (a) levels among the patient population.
Table 3- Lipoprotein levels among cases and controls
Lp(a) < 30 Lp(a) >= 30 Total
Cases 6(10.9%) 49(89.1%) 55(100%)
Control 25(45.5%) 30(54.5%) 55(100%)
The odds ratio was found to be 6.8 with a p value of <0.001(95% CI 2.5-18.5).
E. LOGISTIC REGRESSION ANALYSIS:
Table 4- Logistic regression analysis to check correlation between other atherosclerotic 
risk factors and elevated Lp (a) levels.
Characteristic Unadjusted Adjusted
OR 95% CI P value OR 95% CI P value
Group
Case 6.8 2.5-18.5 <0.001 5.16 1.6-16.8 0.006
Tobacco use
Yes 2.89 1.2-6.8 0.015 1.51 0.5-4.5 0.45
Diabetes
Yes 0.95 0.4-8.3 0.90 0.89 0.3-2.5 0.82
Hypertension
Yes 5.95 1.9-18.6 0.002 5.38 1.6-18.3 0.007
Dyslipidemia
Yes 0.91 0.4-2.4 0.85 0.62 0.2-1.9 0.42
Table 4 indicates that there was a statistically significant association between patients with 
elevated Lp (a) levels and PAOD. However, there was no statistically significant association 
between other atherosclerotic risk factors such as tobacco use, diabetes mellitus, hypertension 
and dyslipidemia, with elevated Lp (a) levels.  
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DISCUSSION
Atherosclerotic peripheral artery occlusive disease shares the same classical risk factors as 
cardiovascular atherosclerotic disease. Elevated Lp (a) levels have been demonstrated in 
patients suffering from cardiovascular disease. We studied 55 patients who presented with 
atherosclerotic PAOD and an equal number of controls who were matched for age and gender 
to see if there is an association between elevated Lp (a) levels and atherosclerotic PAOD. 
The most common presentation among the patients with PAOD was gangrene (either dry or 
wet) followed by claudication and rest pain. There were a few patients who presented with 
acute limb ischemia. Majority of the patients (i.e) 19 (34.54%) presented with gangrene, 16 
(29.09%) with claudication, 15 (27.27%) with rest pain and 5 (9.09%) with acute limb 
ischemia.  Analysis did not show any correlation between the type of presentation and 
elevated Lp (a) levels. 
The risk factor profile was similar to patients with cardiovascular disease. The classical risk 
factors of smoking, diabetes mellitus, hypertension and dyslipidemia were analysed in the 
study.  Among the patients with PAOD 33 (66%) were diabetic, 26(47.27%) were 
hypertensive, 16(29.09%) were dyslipidemic and 45(81.81%) used tobacco. Among the 
control population 37(67.2%) were diabetic, 15(27.27%) were hypertensive, 11(20%) were 
dyslipidemic and 19(34.5%) used tobacco. Thus both cases and controls were exposed to the 
risk factors of atherosclerosis; however the control population did not develop PAOD 
suggesting that there may be other factors which influence the development of PAOD.  
Lp (a) levels have been shown to vary between various ethnic groups, however levels above 
30mg/dl were shown to be associated with an increased risk of cardiovascular disease (104).
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A cut off level of 30mg/dl was used in this study, and patients with values above this value 
were labelled as elevated Lp(a).  
In this study 46 male patients and 9 female patients who presented with atherosclerotic 
PAOD were subjected to a fasting blood sample to analyse the level of Lp(a). An equal 
number of control patients were matched for age and gender and similar samples were 
collected. 
Lp (a) levels more than or equal to 30mg/dl were seen in in 49(89.1%) of the cases. 
Interestingly elevated Lp(a) levels were seen in 30(54.5%) of the control group. The exact 
levels of Lp (a) were significantly higher in the patients with PAOD. The mean Lp (a) level 
among the cases was 103.23mg/dl with a standard deviation of 69.97 and the mean Lp (a) 
level among the controls was 44.58mg/dl with a standard deviation of 38.14.
The reason for this observation may be that the cut off level of 30mg/dl is based on western 
populations. More studies need to be conducted to ascertain the normal range among the 
Indian population. 
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CONCLUSIONS
∑ There was an elevated level of Lp (a) in both cases and controls.
∑ The elevated level was more significant in cases than in controls.
∑ Among the atherosclerotic risk factors only hypertension correlated with an increase 
in Lp (a) levels. 
∑ More data needs to be collected to ascertain the normal level of Lp(a) in the Indian 
population. 
∑ Randomised control trials need to be carried out to assess the effect on Lp (a) 
lowering therapy on patients with PAOD. 
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LIMITATIONS
∑ The sample size that was calculated initially was 58 cases and 58 controls, but only 55 
patients could be enlisted into the study. 
∑ The cut off value that was used for elevated Lp (a) levels is from western literature 
and that may not be an appropriate value among the Indian population.  
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ANNEXURE
VASCULAR SURGERY, CMC HOSPITAL, VELLORE
INPATIENT PROFORMA FOR VASCULAR DISEASE
NAME: AGE: SEX: M / F HOSPITAL NO.:
CONTACT NO.: MOB.: HOME:
Symptom: Claudication   /   Rest pain   /   Gangrene   /   Acute ischaemia
Duration: ------------------ -------------- ---------------- ------------------------
Ischemic symptoms in other systems: Cerebral / cardiac / GIT  /  impotence
Upper limb involvement: Yes / No
Contributory disease: Diabetes / Hypertension / Dyslipidemia / Vasculitis / Homocysteinemia / 
Tobacco use: Cigarette / beedi / tobacco chewing / ------
Family history (vascular) --------------------------------------------------
Past treatment: Medical
Sympathectomy surgical / chemical
Bypass
Debridement
Amputation
Other
Nourishment: Under / Normal / Over 
Blood pressure: Right arm Left arm
Pulses: (-/+ / ++)    Right Left Right Left
Carotid Femoral
Brachial Popliteal
Radial Post tibial
Ulnar Dors. Pedis
Bruit: Yes / No Site:
Superficial thrombophlebitis: Yes / No
Temperature of affected part: Same / warm / cool / cold
Trophic change:  Yes / No
Investigations
PCV
Vasculitic workup: ESR CRP PT (INR)    APTT    VDRL
cANCA    pANCA Rh Factor      ATIII
ANA         dsDNA      LEcells
Lipid profile: Chol. ----- Trig. ------ HDL ----------- LDL --------------
Evidence of ischemic heart disease on ECG, Echo, TMT     Yes / No
70
ABPI:  RIGHT LEFT
Depiction of stenotic lesions N=0to49%, S=50to99%, o=100%
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PATIENT INFORMATION SHEET
1. Study title :-
A case control study to assess the levels of serum lipoprotein A in patients with 
peripheral arterial disease.
2. Principal Investigator :- Dr. Rajesh Selvakumar
Contact address: Department of Vascular Surgery, CMC,Vellore. 
Contact phone/email: 04162282085, drrajeshselvakumar@gmail.com
This study is a research project conducted in CMC Vellore, Department of General 
and Vascular surgery. We want to study the level of serum lipoprotein a  in patients 
with peripheral arterial disease. If you decide to participate in the study, your blood 
sample will be collected for measuring serum lipoprotein a. This is the only 
invasive procedure that you will be subjected to. However this is not an extra 
procedure specific for the study. Even otherwise you will require a blood draw and 
lab tests as part of the standard OPD procedure for treatment purpose. So no extra 
risk is incurred to you due to participation in the study. However all precautions 
necessary will be taken to avoid any complications that may arise due to the 
venepuncture. Preferably a vein at the elbow will be the puncture site. The 
proposed area will be cleaned with spirit and left to dry for 1 min. Puncture will be 
made into the vein (all precautions will be taken to avoid any inadvertent arterial 
puncture) using a 24 G needle and a small amount of blood ( 10 – 15 cc) will be 
collected. After taking out the needle compression will be applied for 1-2 minutes 
to ensure haemostasis. This is all done as a one time process. By participating in 
the study you will not be made to incur any added expenses. Also there is no added 
risk of any kind for you by participating in this study. Any personal information 
about you that is collected as part of this study will be maintained strictly 
confidential.
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INFORMED CONSENT FORM
I …………………………….( Participant’s name), Hosp no…………… have fully 
read and understood the participant’s information sheet  for the study named  “A 
case  control study to assess the levels of serum lipoprotein a in patients with 
peripheral arterial disease “
By signing this form I agree that 
(1) I understand that the purpose of this study is to improve the quality of 
medical care and that my involvement may not benefit me.
(2) I have been made aware of the procedures involved in the study and 
the expected inconvenience, risk, discomfort or potential side effects 
as far as they are currently known by the researcher.
(3) My participation in this study is fully voluntary
I do hereby agree to take part in this study.
Name                       Signature                             Date
Witness1.  Name                        Signature                             Date
Witness2.   Name                       Signature                             Date
